N-terminal prohormone B-type natriuretic peptide variability acts as a predictor of poor prognosis in patients with cardiorenal syndrome type 2

References

• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 [2016];37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J. 2014;35(7):416–418.
   PubMed Web of Science ®Google Scholar
• Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–469.
   PubMed Web of Science ®Google Scholar
• Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539.
   PubMed Web of Science ®Google Scholar
• Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis. 2018;25(5):382–390.
   PubMed Web of Science ®Google Scholar
• House AA, Anand I, Bellomo R, et al. Definition and classification of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. Nephrol Dial Transplant. 2010;25(5):1416–1420.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316–322.
   PubMed Web of Science ®Google Scholar
• Clerico A, Recchia FA, Passino C, et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol. 2006;290(1):H17–29.
   PubMed Web of Science ®Google Scholar
• van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol. 2006;98(3):386–390.
   PubMed Web of Science ®Google Scholar
• Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem. 2007;53(5):866–873.
   PubMed Web of Science ®Google Scholar
• Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in heart failure with preserved ejection fraction study (I-PRESERVE). Circ Heart Fail. 2011;4(1):27–35.
   PubMed Web of Science ®Google Scholar
• Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-Terminal Pro-B-Type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68(22):2425–2436.
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol. 2009;55(1):53–60.
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–392.
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352(7):666–675.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167.
   PubMed Web of Science ®Google Scholar
• Kang SH, Park JJ, Choi DJ, et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart. 2015;101(23):1881–1888.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Wandell P, Dahlstrom U, et al. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: a report from the Swedish heart failure register. Scand J Prim Health Care. 2019;37(4):434–443.
   PubMed Web of Science ®Google Scholar
• Harrison TG, Shukalek CB, Hemmelgarn BR, et al. Association of NT-proBNP and BNP with future clinical outcomes in patients with ESKD: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76(2):233–247.
   PubMed Web of Science ®Google Scholar
• Takahama H, Nishikimi T, Takashio S, et al. Change in the NT-proBNP/Mature BNP molar ratio precedes worsening renal function in patients with acute heart failure: a novel predictor candidate for cardiorenal syndrome. J Am Heart Assoc. 2019;8(17):e011468.
   PubMed Web of Science ®Google Scholar
• Rangaswami J, Bhalla V, Blair J, et al. Mullens Wet al (2019) cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the american heart association. Circulation. 2019;139(16):e840–e878.
   PubMed Web of Science ®Google Scholar
• Mueller C, McDonald K, De Boer RA, et al. Heart failure association of the European society of cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715–731.
   PubMed Web of Science ®Google Scholar
• Panagopoulou V, Deftereos S, Kossyvakis C, et al. NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem. 2013;13(2):82–94.
   PubMed Web of Science ®Google Scholar
• Potocki M, Breidthardt T, Reichlin T, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med. 2010;267(1):119–129.
   PubMed Web of Science ®Google Scholar
• Oremus M, Don-Wauchope A, McKelvie R, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. 2014;19(4):471–505.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52(8):1528–1538.
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278–1283.
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168–2174.
   PubMed Web of Science ®Google Scholar
• Horii M, Matsumoto T, Uemura S, et al. Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. J Cardiol. 2013;61(6):410–416.
   PubMed Web of Science ®Google Scholar
• Cheng YJ, Yao FJ, Liu LJ, et al. B-type natriuretic peptide and prognosis of end-stage renal disease: a meta-analysis. PLoS One. 2013;8(11):e79302.
   PubMed Web of Science ®Google Scholar
• O’Hanlon R, O’Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail. 2007;13(1):50–55.
   PubMed Web of Science ®Google Scholar
• Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to medicare claims. Circ Heart Fail. 2011;4(5):628–636.
   PubMed Web of Science ®Google Scholar
• Cortes R, Rivera M, Salvador A, et al. Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart. 2007;93(8):957–962.
   PubMed Web of Science ®Google Scholar
• Fu S, Ping P, Wang F, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2.
   PubMed Web of Science ®Google Scholar